Of all the cases of economic espionage charged by the DOJ's National Security Division since 2012, more than 80% of them implicated China.World Politicsread more
"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.World Economyread more
Cryptocurrency fans will hope the futures contracts, which are federally regulated, can provide some much-needed legitimacy to bitcoin.Cryptocurrencyread more
Despite mixed fan and critic reactions to the final season of "Game of Thrones," the eight-season epic took home the top prize in the drama category at the Emmy Awards on...Entertainmentread more
There are alternative financial centers and investors can turn to Singapore, Tokyo or Shanghai if Hong Kong doesn't "shape up," says the founder and chairman of Citic Capital.Asia Economyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Tensions between South Korea and Japan may ultimately disrupt the high-end tech sectors, says Heenam Choi, CEO at South Korea's sovereign wealth fund.Traderead more
On Sunday, the 71st Primetime Emmy Awards honored the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
U.S. President Donald Trump's national security advisor said on Sunday that White House Asia policy adviser Matt Pottinger would become his top deputy.Politicsread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
Guardant Health shares popped almost 70 percent in their first day of trading on Thursday.
The Silicon Valley oncology company, backed by SoftBank, sold 12.5 million shares at $19 in its initial public offering. The stock was up more than 80 percent in mid-afternoon trading but later pared some of those gains, closing up 69.47 percent at $32.20 per share.
CEO Helmy Eltoukhy told CNBC on Thursday the company's liquid biopsy, Guardant360, is a "big game changer" when it comes to the detection of cancer.
"Traditionally, late-stage patients would need a tissue biopsy — physically accessing and cutting a piece of their tumor tissue — for the physician to be able to match them with the most effective therapies. We can do that with a simple blood test in about half or a third of the time," he said on "Power Lunch."
Guardant Health matches the results with data to help unlock "tiny signals" in blood and to coordinate those signals with the best possible therapy, he explained.
Right now, the product has been used in 50 different types of cancers, but lung cancer is about 45 percent of the volume because the traditional biopsy is the most difficult and has the highest failure rate, according to Eltoukhy.
But he said the real potential lies in the future.
While the technology is currently being used in late-stage diseases, Guardant Health is looking to make it more sensitive so it can eventually be used for early detection.
"That's really where the power and promise of this technology ultimately lies."
Guardant Health raised $237.5 million in its IPO Thursday.